Acromegaly Treatment Market Size, Share & Trends Analysis Report By Drug Class (Somatostatin Analogs, GHRA, Dopamine Agonists), By Distribution Channel (Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,950	100 Pages	Grand View Research	January, 2025	GV19584417

Best Price Guarantee
Price	from $5,950
Length	100 Pages
Publisher	Grand View Research
Published Date	January, 2025
SKU	GV19584417

Table of Contents
Description

Acromegaly Treatment Market Growth & Trends

The global acromegaly treatment market size is estimated to reach USD 2.37 billion by 2030, registering a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of the acromegaly disease is expected to drive the growth. For instance, the disease prevalence increased fourfold in 2015 from its previous year 2014, according to a report by the Endocrine Society. Moreover, growing investment in clinical trials by various pharmaceutical companies to develop new molecules is another factor propelling the market growth.

Furthermore, strong pipeline of drugs is anticipated to create growth opportunities in the forthcoming years. For instance, Mycapssa by Chiasma Inc. received approval in Europe in 2016. In 2018, Antisense Therapeutics launched their new formulation ALT1103 in U.S. ISIS 766720 by Ionis Pharmaceuticals Inc., a growth hormone receptor antagonist is currently under phase II clinical trial and is expected to be finished by December 2019.

The strong pipeline of drugs for somatostatin analogs is expected to propel growth of the acromegaly treatment market in near future. For instance, in 2018 around 30 clinical trials were being conducted in North America and many are waiting for the U.S. Food and Drug Administration (FDA) approval.

Acromegaly Treatment Market Report Highlights

By drug class, the somatostatin analogues (SSAs) segment captured the largest market share of 65.0% in 2024, owing to their effectiveness in controlling growth hormone levels and managing symptoms.
On the besis of distribution channel, the hospital pharmacies segment garnered the largest share of 49.8% in 2024, attributed to their critical role in providing immediate and specialized care.
North America recorded the largest revenue share of 38.7% in 2024, due to the region’s advanced healthcare infrastructure, high awareness levels, and access to cutting-edge treatments.

Please note The report will be delivered in 2-3 business days upon order notification.

Chapter 1. Methodology and Scope: 1.1. Market Segmentation & Scope; 1.2. Segment Definitions; 1.2.1. Drug Class; 1.2.2. Distribution Channel; 1.3. Estimates and Forecast Timeline; 1.4. Research Methodology; 1.5. Information Procurement; 1.5.1. Purchased Database; 1.5.2. GVR’s Internal Database; 1.5.3. Secondary Sources; 1.5.4. Primary Research; 1.6. Information Analysis; 1.6.1. Data Analysis Models; 1.7. Market Formulation & Data Visualization; 1.8. Model Details; 1.8.1. Commodity Flow Analysis; 1.9. List of Secondary Sources; 1.10. Objectives
Chapter 2. Executive Summary: 2.1. Market Snapshot; 2.2. Segment Snapshot; 2.3. Competitive Landscape Snapshot
Chapter 3. Acromegaly Treatment Market Variables, Trends, & Scope: 3.1. Market Lineage Outlook; 3.2. Market Dynamics; 3.2.1. Market Driver Analysis; 3.2.2. Market Restraint Analysis; 3.3. Business Environment Analysis; 3.3.1. Industry Analysis - Porter’s Five Forces Analysis; 3.3.1.1. Supplier power; 3.3.1.2. Buyer power; 3.3.1.3. Substitution threat; 3.3.1.4. Threat of new entrant; 3.3.1.5. Competitive rivalry; 3.3.2. PESTLE Analysis
Chapter 4. Acromegaly Treatment Market: Drug Class Business Analysis: 4.1. Drug Class Market Share, 2024 & 2030; 4.2. Drug Class Segment Dashboard; 4.3. Market Size & Forecasts and Trend Analysis, By Drug Class, 2018 to 2030 (USD Million); 4.4. Somatostatin Analogues (SSAs); 4.4.1. Somatostatin Analogues (SSAs) Market, 2018 - 2030 (USD Million); 4.5. Growth Hormone Receptor Antagonists (GHRAs); 4.5.1. Growth Hormone Receptor Antagonists (GHRAs) Market, 2018 - 2030 (USD Million); 4.6. Dopamine Agonists; 4.6.1. Dopamine Agonists Market, 2018 - 2030 (USD Million); 4.7. Others; 4.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Acromegaly Treatment Market: Distribution Channel Business Analysis: 5.1. Distribution Channel Market Share, 2024 & 2030; 5.2. Distribution Channel Segment Dashboard; 5.3. Market Size & Forecasts and Trend Analysis, By Distribution Channel, 2018 to 2030 (USD Million); 5.4. Hospital Pharmacies; 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million); 5.5. Retail Pharmacies; 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million); 5.6. Others; 5.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Acromegaly Treatment Market: Regional Estimates & Trend Analysis: 6.1. Regional Market Share Analysis, 2024 & 2030; 6.2. Regional Market Dashboard; 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:; 6.4. North America; 6.4.1. North America Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.4.2. U.S.; 6.4.2.1. Key Country Dynamic; 6.4.2.2. Regulatory Framework; 6.4.2.3. Competitive Insights; 6.4.2.4. U.S. Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.4.3. Canada; 6.4.3.1. Key Country Dynamic; 6.4.3.2. Regulatory Framework; 6.4.3.3. Competitive Insights; 6.4.3.4. Canada Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.4.4. Mexico; 6.4.4.1. Key Country Dynamic; 6.4.4.2. Regulatory Framework; 6.4.4.3. Competitive Insights; 6.4.4.4. Mexico Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.5. Europe; 6.5.1. Europe Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.5.2. UK; 6.5.2.1. Key Country Dynamic; 6.5.2.2. Regulatory Framework; 6.5.2.3. Competitive Insights; 6.5.2.4. UK Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.5.3. Germany; 6.5.3.1. Key Country Dynamic; 6.5.3.2. Regulatory Framework; 6.5.3.3. Competitive Insights; 6.5.3.4. Germany Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.5.4. France; 6.5.4.1. Key Country Dynamic; 6.5.4.2. Regulatory Framework; 6.5.4.3. Competitive Insights; 6.5.4.4. France Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.5.5. Italy; 6.5.5.1. Key Country Dynamic; 6.5.5.2. Regulatory Framework; 6.5.5.3. Competitive Insights; 6.5.5.4. Italy Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.5.6. Spain; 6.5.6.1. Key Country Dynamic; 6.5.6.2. Regulatory Framework; 6.5.6.3. Competitive Insights; 6.5.6.4. Spain Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.5.7. Denmark; 6.5.7.1. Key Country Dynamic; 6.5.7.2. Regulatory Framework; 6.5.7.3. Competitive Insights; 6.5.7.4. Denmark Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.5.8. Norway; 6.5.8.1. Key Country Dynamic; 6.5.8.2. Regulatory Framework; 6.5.8.3. Competitive Insights; 6.5.8.4. Norway Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.5.9. Sweden; 6.5.9.1. Key Country Dynamic; 6.5.9.2. Regulatory Framework; 6.5.9.3. Competitive Insights; 6.5.9.4. Sweden Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.6. Asia Pacific; 6.6.1. Asia Pacific Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.6.2. Japan; 6.6.2.1. Key Country Dynamic; 6.6.2.2. Regulatory Framework; 6.6.2.3. Competitive Insights; 6.6.2.4. Japan Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.6.3. China; 6.6.3.1. Key Country Dynamic; 6.6.3.2. Regulatory Framework; 6.6.3.3. Competitive Insights; 6.6.3.4. China Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.6.4. India; 6.6.4.1. Key Country Dynamic; 6.6.4.2. Regulatory Framework; 6.6.4.3. Competitive Insights; 6.6.4.4. India Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.6.5. South Korea; 6.6.5.1. Key Country Dynamic; 6.6.5.2. Regulatory Framework; 6.6.5.3. Competitive Insights; 6.6.5.4. South Korea Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.6.6. Australia; 6.6.6.1. Key Country Dynamic; 6.6.6.2. Regulatory Framework; 6.6.6.3. Competitive Insights; 6.6.6.4. Australia Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.6.7. Thailand; 6.6.7.1. Key Country Dynamic; 6.6.7.2. Regulatory Framework; 6.6.7.3. Competitive Insights; 6.6.7.4. Thailand Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.7. Latin America; 6.7.1. Latin America Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.7.2. Brazil; 6.7.2.1. Key Country Dynamic; 6.7.2.2. Regulatory Framework; 6.7.2.3. Competitive Insights; 6.7.2.4. Brazil Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.7.3. Argentina; 6.7.3.1. Key Country Dynamic; 6.7.3.2. Regulatory Framework; 6.7.3.3. Competitive Insights; 6.7.3.4. Argentina Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.8. MEA; 6.8.1. MEA Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.8.2. South Africa; 6.8.2.1. Key Country Dynamic; 6.8.2.2. Regulatory Framework; 6.8.2.3. Competitive Insights; 6.8.2.4. South Africa Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.8.3. Saudi Arabia; 6.8.3.1. Key Country Dynamic; 6.8.3.2. Regulatory Framework; 6.8.3.3. Competitive Insights; 6.8.3.4. Saudi Arabia Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.8.4. UAE; 6.8.4.1. Key Country Dynamic; 6.8.4.2. Regulatory Framework; 6.8.4.3. Competitive Insights; 6.8.4.4. UAE Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million); 6.8.5. Kuwait; 6.8.5.1. Key Country Dynamic; 6.8.5.2. Regulatory Framework; 6.8.5.3. Competitive Insights; 6.8.5.4. Kuwait Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape: 7.1. Participant Overview; 7.2. Company Market Position Analysis; 7.3. Company Categorization; 7.4. Strategy Mapping; 7.5. Company Profiles/Listing; 7.5.1. Novartis AG; 7.5.1.1. Overview; 7.5.1.2. Financial Performance; 7.5.1.3. Product Benchmarking; 7.5.1.4. Strategic Initiatives; 7.5.2. Ipsen Pharma; 7.5.2.1. Overview; 7.5.2.2. Financial Performance; 7.5.2.3. Product Benchmarking; 7.5.2.4. Strategic Initiatives; 7.5.3. Sun Pharmaceutical Industries Ltd; 7.5.3.1. Overview; 7.5.3.2. Financial Performance; 7.5.3.3. Product Benchmarking; 7.5.3.4. Strategic Initiatives; 7.5.4. Chiasma, Inc.; 7.5.4.1. Overview; 7.5.4.2. Financial Performance; 7.5.4.3. Product Benchmarking; 7.5.4.4. Strategic Initiatives; 7.5.5. Peptron, Inc.; 7.5.5.1. Overview; 7.5.5.2. Financial Performance; 7.5.5.3. Product Benchmarking; 7.5.5.4. Strategic Initiatives; 7.5.6. WOCKHARDT; 7.5.6.1. Overview; 7.5.6.2. Financial Performance; 7.5.6.3. Product Benchmarking; 7.5.6.4. Strategic Initiatives; 7.5.7. Dauntless Pharmaceuticals; 7.5.7.1. Overview; 7.5.7.2. Financial Performance; 7.5.7.3. Product Benchmarking; 7.5.7.4. Strategic Initiatives; 7.5.8. Pfizer Inc.; 7.5.8.1. Overview; 7.5.8.2. Financial Performance; 7.5.8.3. Product Benchmarking; 7.5.8.4. Strategic Initiatives; 7.5.9. Ionis Pharmaceuticals, Inc.; 7.5.9.1. Overview; 7.5.9.2. Financial Performance; 7.5.9.3. Product Benchmarking; 7.5.9.4. Strategic Initiatives